T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients

Ítems similars

• Adoptive cell therapy with tumor infiltrating lymphocytes and intermediate dose IL-2 for metastatic melanoma
  per: Andersen, Rikke, et al.
  Publicat: (2014)
• Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma
  per: Borch, Troels Holz, et al.
  Publicat: (2020)
• BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer
  per: Donia, Marco, et al.
  Publicat: (2012)
• mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma
  per: Borch, Troels Holz, et al.
  Publicat: (2016)
• Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma
  per: Borch, Troels Holz, et al.
  Publicat: (2021)